Question 1

What is Thymosin Alpha-1?

Accepted Answer

Thymosin Alpha-1 (thymalfasin) is a naturally occurring 28-amino acid peptide derived from the thymic protein prothymosin alpha. It was characterized by Goldstein and colleagues in the 1970s as a thymic hormone with immune regulatory properties. Thymosin Alpha-1 has been studied in preclinical and clinical research for T-cell maturation, NK cell activation, dendritic cell function, and innate immune modulation. It has regulatory approval in multiple countries as Zadaxin for hepatitis B and C treatment.

Question 2

How does Thymosin Alpha-1 work in research models?

Accepted Answer

In preclinical research models, Thymosin Alpha-1 activates Toll-like receptors (TLR2 and TLR9) on dendritic cells and immune cells, driving NF-kB signaling and Type I interferon production. Downstream effects include dendritic cell maturation with upregulation of co-stimulatory molecules, enhanced T-cell proliferation and CD4+/CD8+ ratio normalization, and NK cell cytotoxic function activation. See /how-thymosin-alpha-1-works/ for the complete mechanism overview.

Question 3

What has Thymosin Alpha-1 been studied for in published research?

Accepted Answer

Published research has examined Thymosin Alpha-1 in hepatitis B and C clinical trials (supporting FDA and international regulatory approval), HIV infection preclinical and clinical models, cancer immunotherapy as an immune adjuvant, sepsis and post-sepsis immune paralysis models, immunosenescence research in aged rodent models, and general T-cell and NK cell activation studies.

Question 4

What is Thymosin Alpha-1's half-life in research models?

Accepted Answer

Published pharmacokinetic data for Thymosin Alpha-1 documents a relatively short plasma half-life of approximately 2 hours in clinical pharmacokinetic studies. This pharmacokinetic profile has informed the administration frequency in published clinical trial designs. The thymic peptide structure is subject to proteolytic degradation in plasma, with published studies characterizing intact peptide levels using HPLC or immunoassay methods.

Question 5

How is Thymosin Alpha-1 stored for research use?

Accepted Answer

Research-grade Thymosin Alpha-1 should be stored as lyophilized powder at -20 degrees Celsius for long-term stability. The FDA-approved Zadaxin formulation provides reference standards for lyophilized formulation stability. Reconstituted solutions should be prepared in appropriate aqueous vehicle and used within the handling period specified by the supplier or consistent with published clinical formulation methodology.

Question 6

What purity standard should research-grade Thymosin Alpha-1 meet?

Accepted Answer

Research-grade Thymosin Alpha-1 should meet at least 98% purity by HPLC analysis with mass spectrometry molecular weight confirmation of the 28-amino acid sequence. Certificate of Analysis should include sequence verification, purity result, and endotoxin testing if intended for cell culture immunology applications where endotoxin interference with immune endpoints is a concern.

Question 7

Is Thymosin Alpha-1 water soluble?

Accepted Answer

Thymosin Alpha-1 is water soluble and is typically prepared in sterile saline or water for research applications. The commercial Zadaxin product is formulated as a lyophilized cake reconstituted in diluent for clinical injection, providing a reference formulation framework. For in vitro immunology research, reconstitution in sterile PBS or culture media-compatible vehicle is standard practice.

Question 8

What clinical research has been published on Thymosin Alpha-1?

Accepted Answer

Thymosin Alpha-1 has one of the more substantial clinical research bodies among research peptides. Randomized controlled trials published in hepatology journals support its clinical approval for hepatitis B and C in multiple countries. Additional published clinical research covers HIV infection, cancer immunotherapy, and sepsis management. These clinical publications provide pharmacokinetic, safety, and efficacy data that serve as reference for preclinical research protocol design.

Question 9

How does Thymosin Alpha-1 compare to KPV in immune research?

Accepted Answer

Thymosin Alpha-1 and KPV approach immune modulation through entirely different mechanisms in published research. Thymosin Alpha-1 modulates adaptive immunity through T-cell maturation, dendritic cell activation, and NK cell function. KPV modulates innate inflammatory signaling through NF-kB pathway inhibition in epithelial and immune cells. These compounds address different aspects of immune regulation and have been studied in different primary model systems without substantial direct comparison in the published literature.

Question 10

Where can researchers source Thymosin Alpha-1 for in vitro research?

Accepted Answer

Research-grade Thymosin Alpha-1 for in vitro immunology research is available from Spartan Peptides with at least 98% HPLC-verified purity and Certificate of Analysis documentation. All Thymosin Alpha-1 is for in vitro research use only. Researchers sourcing Thymosin Alpha-1 for immunology work should request endotoxin test results (LAL assay) in COA documentation due to potential LPS interference with immune endpoint measurements.

Question 11

What is the molecular weight of Thymosin Alpha-1?

Accepted Answer

Thymosin Alpha-1 as a 28-amino acid peptide has a molecular weight of approximately 3108 Daltons. This value is the reference for mass spectrometry verification in COA documentation. The Zadaxin clinical product pharmacokinetic data provides published reference values for plasma concentration and clearance based on this molecular weight in clinical dose-response studies.

Question 12

What TLR receptor research has been published for Thymosin Alpha-1?

Accepted Answer

Published mechanistic research has characterized Thymosin Alpha-1 activating TLR2 and TLR9 on plasmacytoid dendritic cells and conventional dendritic cell populations. TLR9 activation through CpG-DNA-like signaling has been documented in publications examining type I interferon production following Thymosin Alpha-1 treatment. This TLR-NF-kB mechanism distinguishes Thymosin Alpha-1 from thymosin-beta-4 (TB-500), which acts through completely different actin cytoskeletal mechanisms.

Question 13

Does Thymosin Alpha-1 cross the blood-brain barrier in research models?

Accepted Answer

Published research on Thymosin Alpha-1 has focused primarily on peripheral immune system effects, with limited published data on CNS distribution. The 3108 Dalton molecular weight is above the typical threshold for passive BBB penetration. Some published research has examined Thymosin Alpha-1 effects on neuroinflammation from the perspective of peripheral immune modulation affecting CNS inflammatory status rather than direct CNS access.

Question 14

What purity should researchers look for when sourcing Thymosin Alpha-1?

Accepted Answer

Research-grade Thymosin Alpha-1 should meet at least 98% purity by HPLC with mass spectrometry confirmation of the 28-amino acid sequence molecular weight around 3108 Da. For immunology research applications, endotoxin testing (LAL assay) in COA documentation is particularly important, since even low endotoxin levels can activate TLR4 pathways in immune cells and confound Thymosin Alpha-1 TLR2/TLR9 mechanism research. Batch-specific documentation is essential.

Question 15

How do researchers verify a certificate of analysis for Thymosin Alpha-1?

Accepted Answer

A valid Thymosin Alpha-1 COA should include HPLC purity with chromatogram, mass spectrometry data confirming molecular weight around 3108 Da, endotoxin test results (ideally below 1 EU/mg for cell culture immunology use), batch number, and testing date. The Zadaxin approved product specifications provide a reference quality standard that researchers can use to evaluate research-grade material COA completeness.

Question 16

What research has been published on Thymosin Alpha-1 in sepsis models?

Accepted Answer

Published clinical and preclinical research has examined Thymosin Alpha-1 in sepsis-induced immunosuppression models, where post-sepsis immune paralysis (reduced T-cell and NK cell function) represents a major clinical problem. Clinical trials in septic patients have documented Thymosin Alpha-1 improving immune function parameters including T-cell counts and NK cell activity. These sepsis-immune paralysis publications from Chinese clinical research groups represent a substantial portion of the recent Thymosin Alpha-1 clinical literature.

Question 17

What NK cell research has been published on Thymosin Alpha-1?

Accepted Answer

Published immunology research has characterized Thymosin Alpha-1 enhancing NK cell cytotoxic function through dendritic cell-mediated IL-12 and interferon-gamma production. NK cell activation by Thymosin Alpha-1 is primarily indirect, proceeding through dendritic cell maturation and cytokine release rather than direct NK cell receptor engagement. Published anti-tumor immunity research has measured NK cell activity as an endpoint in Thymosin Alpha-1 cancer model studies.

Question 18

What's the difference between research-grade and pharmaceutical-grade Thymosin Alpha-1?

Accepted Answer

Research-grade Thymosin Alpha-1 is characterized for HPLC purity and mass spectrometry identity for in vitro immunology use. Zadaxin (thymalfasin) as the pharmaceutical product underwent GMP manufacturing, sterility testing, endotoxin characterization, and full regulatory review for clinical injection. Research-grade Thymosin Alpha-1 for cell culture use must at minimum have low endotoxin documentation to be useful for immune cell assays. These are meaningfully different quality tiers.

Question 19

What immunosenescence research has been published for Thymosin Alpha-1?

Accepted Answer

Published immunosenescence research has characterized Thymosin Alpha-1 effects on immune function parameters in aged rodent models, including CD4+/CD8+ T-cell ratio normalization and NK cell activity restoration. Goldstein's foundational thymic hormone research program established thymalfasin as a thymic aging research compound, and subsequent publications have examined whether exogenous Thymosin Alpha-1 can partially restore immune function parameters documented to decline with thymic involution.

Question 20

What does HPLC verification mean for Thymosin Alpha-1 quality?

Accepted Answer

HPLC verification for Thymosin Alpha-1 separates the intact 28-amino acid peptide from synthesis truncations and degradation products. At 28 amino acids, synthesis complexity means truncation products are a realistic concern, and HPLC chromatogram review plus MS confirmation is the appropriate analytical standard. Endotoxin testing alongside HPLC purity is the additional critical quality parameter for this immune research compound.

Question 21

Why does batch-to-batch consistency matter for Thymosin Alpha-1 research?

Accepted Answer

Batch consistency for Thymosin Alpha-1 immunology research is critical because variable endotoxin levels between batches would produce variable TLR4 activation that confounds the TLR2/TLR9 mechanism being studied. Variable peptide purity affecting TLR agonist activity would also produce non-reproducible immune activation results. Researchers running T-cell or NK cell activation assays should document batch numbers and verify both purity and endotoxin COA data for each supply replenishment.

Question 22

What animal models are used in published Thymosin Alpha-1 immune research?

Accepted Answer

Published Thymosin Alpha-1 preclinical research has used C57BL/6 and BALB/c mouse models for tumor immunology and viral infection research, Wistar rats for pharmacokinetic characterization, and in vitro human PBMC (peripheral blood mononuclear cell) cultures for direct immune cell mechanistic studies. The availability of clinical trial data from Zadaxin approval trials provides human reference data that is less common for most research peptides.

Question 23

Has Thymosin Alpha-1 been studied in combination with other immune research compounds?

Accepted Answer

Published cancer immunotherapy research has examined Thymosin Alpha-1 in combination with cytokines including IFN-alpha in hepatitis and tumor models. Clinical trial designs have also examined Thymosin Alpha-1 as an immune adjuvant added to standard antiviral therapy protocols. These published combination designs provide reference frameworks for researchers designing in vitro combination immunology experiments with Thymosin Alpha-1 and cytokine co-stimulatory agents.

Question 24

What sourcing considerations apply to Thymosin Alpha-1 for in vitro immunology research?

Accepted Answer

Endotoxin content is the most critical sourcing consideration for Thymosin Alpha-1 in cell culture immunology research. Even low endotoxin levels activate TLR4 on immune cells, creating non-specific immune activation that confounds TLR2/TLR9 mechanism studies. Spartan Peptides provides research-grade Thymosin Alpha-1 with endotoxin documentation in COA alongside HPLC purity and mass spectrometry verification for in vitro immunology applications.

GLP-3(Reta) | Triple-Agonist Metabolic Research

NAD+ 750mg | Cellular Energy & DNA Repair Research

MOTS-c | Mitochondrial Metabolism Research Peptide

BPC-157 5mg | Tissue Repair & Gut Health Research

Thymosin Alpha-1 Frequently Asked Questions

Explore Full Research Index